General Announcement::Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
21-Dec-2020 13:05:39
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules
Announcement Reference
SG201221OTHR1BHD
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
21/12/2020 10:35:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg

Attachments

SGX_PR_21122020.pdf
Total size =799K